-
EP3397273
European procedure
Extract from the Register of European Patents
EP About this file: EP3397273
| EP3397273 - AUGMENTED ACID ALPHA-GLUCOSIDASE FOR THE TREATMENT OF POMPE DISEASE [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 25.03.2022 Database last updated on 26.04.2025 | |
| Former | The patent has been granted Status updated on 16.04.2021 | ||
| Former | Grant of patent is intended Status updated on 17.02.2021 | ||
| Former | Examination is in progress Status updated on 18.12.2019 | ||
| Former | Request for examination was made Status updated on 05.10.2018 | ||
| Former | The international publication has been made Status updated on 07.07.2017 | ||
| Former | unknown Status updated on 27.01.2017 | Most recent event Tooltip | 25.03.2022 | No opposition filed within time limit | published on 27.04.2022 [2022/17] | Applicant(s) | For all designated states Amicus Therapeutics, Inc. 3675 Market Street Philadelphia, PA 19104 / US | [2021/14] |
| Former [2018/45] | For all designated states Amicus Therapeutics, Inc. 1 Cedar Brook Drive Cranbury, NJ 08512 / US | Inventor(s) | 01 /
DO, Hung V. 1 Cedarbrook Drive Cranbury, New Jersey 08512 / US | 02 /
KHANNA, Richie 1 Cedar Brook Drive Cranbury, New Jersey 08512 / US | 03 /
GOTSCHALL, Russell 1 Cedar Brook Drive Cranbury, New Jersey 08512 / US | [2018/45] | Representative(s) | Miller Sturt Kenyon 9 John Street London WC1N 2ES / GB | [2018/45] | Application number, filing date | 16826898.5 | 29.12.2016 | [2018/45] | WO2016US69243 | Priority number, date | US201562272890P | 30.12.2015 Original published format: US 201562272890 P | US201662300479P | 26.02.2016 Original published format: US 201662300479 P | US201662315412P | 30.03.2016 Original published format: US 201662315412 P | US201662402454P | 30.09.2016 Original published format: US 201662402454 P | US201662428867P | 01.12.2016 Original published format: US 201662428867 P | US201662431791P | 08.12.2016 Original published format: US 201662431791 P | [2018/45] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2017117407 | Date: | 06.07.2017 | Language: | EN | [2017/27] | Type: | A1 Application with search report | No.: | EP3397273 | Date: | 07.11.2018 | Language: | EN | The application published by WIPO in one of the EPO official languages on 06.07.2017 takes the place of the publication of the European patent application. | [2018/45] | Type: | B1 Patent specification | No.: | EP3397273 | Date: | 19.05.2021 | Language: | EN | [2021/20] | Search report(s) | International search report - published on: | EP | 06.07.2017 | Classification | IPC: | A61K38/47, A61K31/445 | [2018/45] | CPC: |
A61K38/47 (EP,US);
A61K31/05 (EP);
A61K31/445 (EP,US);
A61P43/00 (EP);
C12Y302/0102 (EP,US)
| C-Set: |
A61K31/05, A61K2300/00 (EP);
A61K31/445, A61K2300/00 (EP) | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/45] | Extension states | BA | 30.07.2018 | ME | 30.07.2018 | Validation states | MA | Not yet paid | MD | Not yet paid | Title | German: | AUGMENTIERTE ALPHA-GLUCOSIDASE ZUR BEHANDLUNG VON MORBUS POMPE | [2018/45] | English: | AUGMENTED ACID ALPHA-GLUCOSIDASE FOR THE TREATMENT OF POMPE DISEASE | [2018/45] | French: | ALPHA-GLUCOSIDASE ACIDE AMÉLIORÉE POUR LE TRAITEMENT DE LA MALADIE DE POMPE | [2018/45] | Entry into regional phase | 30.07.2018 | National basic fee paid | 30.07.2018 | Designation fee(s) paid | 30.07.2018 | Examination fee paid | Examination procedure | 30.07.2018 | Examination requested [2018/45] | 30.07.2018 | Date on which the examining division has become responsible | 14.02.2019 | Amendment by applicant (claims and/or description) | 02.01.2020 | Despatch of a communication from the examining division (Time limit: M06) | 02.07.2020 | Reply to a communication from the examining division | 15.10.2020 | Despatch of a communication from the examining division (Time limit: M04) | 17.12.2020 | Reply to a communication from the examining division | 18.02.2021 | Communication of intention to grant the patent | 12.04.2021 | Fee for grant paid | 12.04.2021 | Fee for publishing/printing paid | 12.04.2021 | Receipt of the translation of the claim(s) | Divisional application(s) | EP21174249.9 / EP3957320 | EP23188938.7 | Opposition(s) | 22.02.2022 | No opposition filed within time limit [2022/17] | Fees paid | Renewal fee | 12.12.2018 | Renewal fee patent year 03 | 13.12.2019 | Renewal fee patent year 04 | 14.12.2020 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XP]WO2016054231 (AMICUS THERAPEUTICS INC [US]); | by applicant | WO2004069190 | WO2006125141 | WO2013166249 | US8592362 | WO2014014938 |